Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Docetaxel
Drug ID BADD_D00699
Description Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel reversibly binds to tubulin with high affinity in a 1:1 stoichiometric ratio
Indications and Usage For the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Also used as a single agent in the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. It is also used in combination with prednisone, in the treatment of patients with androgen independent (hormone refractory) metastatic prostate cancer. Furthermore, docetaxel has uses in the treatment of gastric adenocarinoma and head and neck cancer.
Marketing Status Prescription; Discontinued
ATC Code L01CD02
DrugBank ID DB01248
KEGG ID D02165
MeSH ID D000077143
PubChem ID 148124
TTD Drug ID D0O5WP
NDC Product Code 0955-1022; 67457-781; 45963-765; 47335-323; 57884-3042; 66758-050; 43598-611; 43598-258; 54893-0008; 0409-5068; 43598-389; 55150-378; 0955-1020; 72485-214; 0409-0368; 70700-176; 68083-401; 70700-174; 65129-1189; 70121-1223; 65129-1298; 0143-9204; 65129-1141; 47335-895; 0143-9205; 55150-379; 57884-3041; 47335-939; 70121-1222; 70700-175; 0409-4235; 17359-9100; 0409-0367; 16729-267; 68083-400; 68554-0075; 43066-001; 0409-0365; 43066-010; 72485-215; 66758-950; 43598-259; 55150-380; 70747-1004; 68083-399; 70121-1221; 45963-734; 0955-1021; 0409-0366; 43066-006; 43598-610; 72485-216; 57884-3043
Synonyms Docetaxel | Docetaxel Trihydrate | Docetaxol | Docetaxel Hydrate | Taxoltere Metro | RP 56976 | RP-56976 | RP56976 | Taxotere | Docetaxel Anhydrous | N-Debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol | N Debenzoyl N tert butoxycarbonyl 10 deacetyltaxol | NSC 628503
Chemical Information
Molecular Formula C43H53NO14
CAS Registry Number 114977-28-5
SMILES CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O) O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Cell deathCaspase-3P42574T57943Not Available
Cell deathApoptosis regulator Bcl-2P10415T31309Not Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypersensitivity10.01.03.0030.003197%
Hypertension24.08.02.001--
Hypertensive crisis24.08.01.0010.000533%Not Available
Hyperthermia12.05.01.002; 08.05.01.0010.000139%Not Available
Hypoaesthesia17.02.06.023--Not Available
Hypocalcaemia14.04.01.0040.000533%
Hyponatraemia14.05.04.002--
Hypotension24.06.03.002--
Hypoxia22.02.02.0030.001332%
Ileus07.13.01.0010.000208%
Immune system disorder10.02.01.001--Not Available
Infection11.01.08.002--Not Available
Influenza like illness08.01.03.010--
Injection site infection12.07.03.008; 11.01.08.005; 08.02.03.019--Not Available
Injection site reaction08.02.03.014; 12.07.03.015--
Insomnia19.02.01.002; 17.15.03.002--
Interstitial lung disease22.01.02.003; 10.02.01.0330.000903%Not Available
Intestinal ischaemia24.04.08.001; 07.15.02.0010.000347%Not Available
Intestinal obstruction07.13.01.002--Not Available
Jaundice09.01.01.004; 01.06.04.004; 23.03.03.030--Not Available
Lacrimation increased06.08.02.004--
Large intestine perforation12.02.03.005; 07.04.06.0050.000139%
Laryngeal pain22.02.05.036--
Laryngospasm22.04.02.0020.000533%
Lethargy19.04.04.004; 17.02.04.003; 08.01.01.008--
Leukopenia01.02.02.0010.007726%Not Available
Lip swelling10.01.05.005; 07.05.04.005; 23.04.01.0070.000533%Not Available
Liver disorder09.01.08.001--Not Available
Liver function test abnormal13.03.01.013--Not Available
Local swelling08.01.03.0130.000533%Not Available
The 6th Page    First    Pre   6 7 8 9 10    Next   Last    Total 15 Pages